ACH
MLTX icon

ArrowMark Colorado Holdings’s MoonLake Immunotherapeutics MLTX Stock Holding History

ArrowMark Colorado Holdings’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,000
Closed -$570K – 315
2023
Q3 		$570K Hold
10,000
– – 0.01% 274
2023
Q2 		$510K Buy
+10,000
New +$269K 0.01% 270

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

ArrowMark Colorado Holdings's MLTX Position: Q4 2023 in Review

ArrowMark Colorado Holdings sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2023, closing a stake of 10,000 shares — an estimated $570K sold.

ArrowMark Colorado Holdings first reported a position in MLTX in Q2 2023 and held it in 2 quarters. The position peaked at $570K in Q3 2023. 125 funds tracked by Wall St. Rank hold MLTX as of Q4 2023.

  • ArrowMark Colorado Holdings reported no remaining MoonLake Immunotherapeutics position as of Q4 2023 after selling out during the quarter.
  • ArrowMark Colorado Holdings sold 10,000 MoonLake Immunotherapeutics shares in Q4 2023, an estimated $570K.
  • ArrowMark Colorado Holdings first reported a position in MoonLake Immunotherapeutics in Q2 2023 and held it in 2 quarters.
  • ArrowMark Colorado Holdings's MoonLake Immunotherapeutics position peaked at $570K in Q3 2023.
  • 125 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2023.

Based on ArrowMark Colorado Holdings's 13F filing for Q4 2023, filed 14 Feb 2024.